Long-term responders and survivors on pazopanib for advanced soft tissue sarcomas: Subanalysis of two European Organisation for Research and Treatment of Cancer (EORTC) clinical trials 62043 and 62072

Annals of Oncology

Volumn 25, Issue 3, 2014, Pages 719-724

  Kasper, B ^a   Sleijfer, S ^b   Litiere S ^c   Marreaud, S ^c   Verweij, J ^b   Hodge, R A ^d   Bauer, S ^e   Kerst, J M ^f   van der Graaf, W T A ^g  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b ERASMUS MC CANCER INSTITUTE   (Netherlands)

^c EORTC DATA CENTER   (Belgium)

^d GLAXOSMITHKLINE   (United Kingdom)

^e UNIVERSITY HOSPITAL ESSEN   (Germany)

^f NETHERLANDS CANCER INSTITUTE   (Netherlands)

^g RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

EORTC; Long term responders; Long term survivors; Pazopanib; Soft tissue sarcoma; STBSG

Indexed keywords

PAZOPANIB;

ADULT; AGE DISTRIBUTION; ARTICLE; CANCER GRADING; CANCER PROGNOSIS; CANCER SURVIVAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESPONSE; DRUG WITHDRAWAL; FEMALE; HUMAN; LONG TERM SURVIVAL; LUNG EMBOLISM; MALE; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SEX DIFFERENCE; SHORT TERM SURVIVAL; SOFT TISSUE SARCOMA; SURVIVAL RATE; TREATMENT DURATION;

EORTC; LONG-TERM RESPONDERS; LONG-TERM SURVIVORS; PAZOPANIB; SOFT TISSUE SARCOMA; STBSG;

ADULT; AGED; ANGIOGENESIS INHIBITORS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PLACEBOS; PYRIMIDINES; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; RETROSPECTIVE STUDIES; SARCOMA; SULFONAMIDES; TREATMENT OUTCOME;

EID: 84896877553     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdt586     Document Type: Article

References (19)

1. Kasper B, Hohenberger P. Pazopanib: a promising new agent in the treatment of soft tissue sarcomas. Future Oncol 2011; 7: 1373-1383.
2. Blay JY, van Glabbeke M, Verweij J et al. Advanced soft-tissue sarcoma: a disease that is potentially curable for a subset of patients treated with chemotherapy. Eur J Cancer 2003; 39: 64-69.
3. Harris PA, Boloor A, Cheung M et al. Discovery of 5-[[4-[(2,3-Dimethyl-2H-indazol-6-yl)methylamino]-2 pyrimidinyl]amino] 2 methylbenzenesulfonamide (pazopanib), a novel and potent vascular endothelial growth factor receptor inhibitor. J Med Chem 2008; 51: 4632-4640.
4. Hurwitz HI, Dowlati A, Saini S et al. Phase I trial of pazopanib (GW786034), an oral multikinase angiogenesis inhibitor, in patients with advanced cancer: results of safety, pharmacokinetics, and clinical activity. Clin Cancer Res 2009; 15: 4220-4227.
5. Keisner SV, Shah SR. Pazopanib-the newest tyrosine kinase inhibitor for the treatment of advanced or metastatic renal cell carcinoma. Drugs 2011; 71: 443-454.
6. Sleijfer S, Ray-Coquard I, Papai Z et al. Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European Organisation for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTC Study 62043). J Clin Oncol 2009; 27: 3126-3132.
7. Van der Graaf WTA, Blay JY, Chawla SP et al. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2012; 379: 1879-1886.
8. Van Glabbeke M, Verweij J, Judson J et al. Progression-free rate as the principal end point for phase II trials in soft tissue sarcomas. Eur J Cancer 2002; 38: 543-549.
9. Andersen PK, Klein JP, Rosthoj S. Generalized linear models for correlated pseudo-observations with applications to multi-state models. Biometrika 2003; 90: 15-27.
10. Klein JP, Logan B, HarhoffM et al. Analyzing survival curves at a fixed point in time. Stat Med 2007; 26: 4505-4519.
11. Le Cesne A, Blay JY, Judson I et al. Phase II study of ET-743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trial. J Clin Oncol 2005; 23: 576-584.
12. Schöffski P, Ray-Coquard IL, CioffiA et al. Activity of eribulin mesylate in patients with soft-tissue sarcoma: a phase 2 study in four independent histological subtypes. Lancet Oncol 2011; 12: 1045-1052.
13. Olmos D, Ang JE, Gomez-Roca C et al. Pitfalls and limitations of a single-centre, retrospectively derived prognostic score for phase I oncology trial participants-reply to Fussenich et al.: a new, simple and objective prognostic score for phase I cancer patients. Eur J Cancer 2012; 48: 594-596.
14. HoffCM. Importance of hemoglobin concentration and its modification for the outcome of head and neck cancer patients treated with radiotherapy. Acta Oncol 2012; 51: 419-432.
15. Stefanovski PD, Bidoli E, De Paoli A et al. Prognostic factors in soft tissue sarcomas: a study of 395 patients. Eur J Surg Oncol 2002; 28: 153-164.
16. Sleijfer S, Ouali M, van Glabbeke M et al. Prognostic and predictive factors for outcome to first-line ifosfamide-containing chemotherapy for adult patients with advanced soft tissue sarcomas: an exploratory, retrospective analysis on large series from the European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTC-STBSG). Eur J Cancer 2010; 46: 72-83.
17. V Glabbeke M, van Oosterom AT, Oosterhuis JW et al. Prognostic factors for the outcome of chemotherapy in advanced soft tissue sarcoma: an analysis of 2.185 patients treated with anthracycline-containing first-line regimens -a European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study. J Clin Oncol 1999; 17: 150-157.
18. Ray-Coquard I, Cropet C, Van Glabbeke M et al. Lymphopenia as a prognostic factors for overall survival in advanced carcinomas, sarcomas, and lymphomas. Cancer Res 2009; 69: 5383-5391.
19. Sleijfer S, Gorlia T, Lamers C et al. Cytokine and angiogenic factors associated with efficacy and toxicity of pazopanib in advanced soft-tissue sarcoma: an EORTC-STBSG study. Br J Cancer 2012; 107: 639-645.